



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: **Varenicline-d4 Dihydrochloride (Major)**

CAS 号: **866823-63-4**

产品货号: **S88198**

生物活性:

Description	Varenicline (CP 526555) 是具有口服活性的尼古丁依赖主要介质 $\alpha 4 \beta 2$ 烟碱型乙酰胆碱受体 ($\alpha 4 \beta 2$ nAChR) 的部分激动剂 ($IC_{50} = 250$ nM)。Varenicline 也是 $\alpha 6 \beta 2$ nAChR 的部分激动剂和 $\alpha 7 \beta 2$ nAChR 的完全激动剂。Varenicline 可阻断尼古丁对 nAChR 的直接激动作用, 同时以更温和的程度刺激 nAChR, 被广泛用作戒烟的辅助手段。																								
IC50 & Target	EC50: 2.3 μ M ($\alpha 4 \beta 2$ nAChR); 18 μ M ($\alpha 7$ nAChR); 55 μ M ($\alpha 3 \beta 4$ nAChR)[2]																								
In Vitro	Varenicline (200 μM, 24 h) 对 HUVEC 细胞活力无明显影响[3]。 Varenicline (100 μM, 30 min) 显著激活 HUVEC 细胞中的 ERK1/2 和 p38 信号通路, 因而 Varenicline (100 μM, 24 h) 降低 HUVEC 细胞中 VE-cadherin 的表达[3]。 Varenicline (100 μM, 4 h) 促进 HUVEC 细胞 2.4 倍的细胞迁移[3]。 Cell Viability Assay[3] <table><tr><td>Cell Line:</td><td>HUVEC</td></tr><tr><td>Concentration:</td><td>100, 200, 300, 500 μM</td></tr><tr><td>Incubation Time:</td><td>24 h</td></tr><tr><td>Result:</td><td>Did not affect cell viability at 100 and 200 μM ($96.8 \pm 0.1\%$ and $93.9 \pm 1.8\%$, respectively). Decreased cell viability to $85.7 \pm 7.5\%$ and $57.8 \pm 7.7\%$ for 300 and 500 μM, respectively.</td></tr></table> Western Blot Analysis[3] <table><tr><td>Cell Line:</td><td>HUVEC</td></tr><tr><td>Concentration:</td><td>100 μM</td></tr><tr><td>Incubation Time:</td><td>1, 5, 10, 15, 30, 60 min, 24 h</td></tr><tr><td>Result:</td><td>Significantly activated ERK1/2 and p38 signaling with peak activity at 10–15 min and 10–30 min after treatment, respectively, lowered expression of VE-cadherin at 24 h. MLA (100 nM) significantly reversed the Varenicline-induced effects.</td></tr></table> Cell Migration Assay [3] <table><tr><td>Cell Line:</td><td>HUVEC</td></tr><tr><td>Concentration:</td><td>100, 200, 300, 500 μM</td></tr><tr><td>Incubation Time:</td><td>4 h</td></tr><tr><td>Result:</td><td>Significantly increased the number of migrating cells by 2.4-fold compared with vehicle treatment. MLA (100 nM) completely blocked Varenicline-stimulated migration.</td></tr></table>	Cell Line:	HUVEC	Concentration:	100, 200, 300, 500 μ M	Incubation Time:	24 h	Result:	Did not affect cell viability at 100 and 200 μ M ($96.8 \pm 0.1\%$ and $93.9 \pm 1.8\%$, respectively). Decreased cell viability to $85.7 \pm 7.5\%$ and $57.8 \pm 7.7\%$ for 300 and 500 μ M, respectively.	Cell Line:	HUVEC	Concentration:	100 μ M	Incubation Time:	1, 5, 10, 15, 30, 60 min, 24 h	Result:	Significantly activated ERK1/2 and p38 signaling with peak activity at 10–15 min and 10–30 min after treatment, respectively, lowered expression of VE-cadherin at 24 h. MLA (100 nM) significantly reversed the Varenicline-induced effects.	Cell Line:	HUVEC	Concentration:	100, 200, 300, 500 μ M	Incubation Time:	4 h	Result:	Significantly increased the number of migrating cells by 2.4-fold compared with vehicle treatment. MLA (100 nM) completely blocked Varenicline-stimulated migration.
Cell Line:	HUVEC																								
Concentration:	100, 200, 300, 500 μ M																								
Incubation Time:	24 h																								
Result:	Did not affect cell viability at 100 and 200 μ M ($96.8 \pm 0.1\%$ and $93.9 \pm 1.8\%$, respectively). Decreased cell viability to $85.7 \pm 7.5\%$ and $57.8 \pm 7.7\%$ for 300 and 500 μ M, respectively.																								
Cell Line:	HUVEC																								
Concentration:	100 μ M																								
Incubation Time:	1, 5, 10, 15, 30, 60 min, 24 h																								
Result:	Significantly activated ERK1/2 and p38 signaling with peak activity at 10–15 min and 10–30 min after treatment, respectively, lowered expression of VE-cadherin at 24 h. MLA (100 nM) significantly reversed the Varenicline-induced effects.																								
Cell Line:	HUVEC																								
Concentration:	100, 200, 300, 500 μ M																								
Incubation Time:	4 h																								
Result:	Significantly increased the number of migrating cells by 2.4-fold compared with vehicle treatment. MLA (100 nM) completely blocked Varenicline-stimulated migration.																								
In Vivo	Varenicline (0.5, 1mg/kg, 皮下注射, 即刻给药) 剂量依赖性地逆转芬太尼引起的大鼠呼吸抑制, 同时轻度缓解芬太尼的镇静效果[4]。 Varenicline (0.004 - 0.04 mg/kg/h, 静脉滴注, 一日 23h, 7-10 d) 剂量依赖性地减少有可卡因和尼古丁使用经验的成年恒河猴对尼古丁 (0.0032 mg/kg/inj) 单独使用, 以及可与可卡因 (0.0032 mg/kg/inj) 联合使用的自我给药水平, 且对食物维持反应无显著影响[5]。 Varenicline (0.178-5.6 mg/kg, 口服, 即刻给药) 在 C57BL/6J 和 CD-1 小鼠的强迫游泳实验中显示出抗抑郁样活性[6]。																								
	细胞实验:																								



Solvent&Solubility	H2O 中的溶解度 : $\geq 100 \text{ mg/mL}$ (351.89 mM)				
	DMSO 中的溶解度 : 62.5 mg/mL (219.93 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响, 请使用新开封的 DMSO)				
	* " $\geq$ " means soluble, but saturation unknown.				
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
		1 mM	3.5189 mL	17.5945 mL	35.1890 mL
5 mM		0.7038 mL	3.5189 mL	7.0378 mL	
10 mM		0.3519 mL	1.7594 mL	3.5189 mL	
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。 * 备注: 如您选择水作为储备液, 请稀释至工作液后, 再用 0.22 μm 的滤膜过滤除菌后使用。					
参考文献	[1]. Koegelenberg CF, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014 Jul;312(2):155-61. [2]. Magnus CJ, et al. Ultrapotent chemogenetics for research and potential clinical applications. Science. 2019;364(6436):eaav5282. [3]. Koga M, et al. Varenicline promotes endothelial cell migration by lowering vascular endothelial-cadherin levels via the activated $\alpha 7$ nicotinic acetylcholine receptor-mitogen activated protein kinase axis. Toxicology. 2017;390:1-9. [4]. Ren J, et al. Countering Opioid-induced Respiratory Depression in Male Rats with Nicotinic Acetylcholine Receptor Partial Agonists Varenicline and ABT 594. Anesthesiology. 2020 May;132(5):1197-1211. [5]. Mello NK, et al. Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotine+cocaine self-administration. Neuropsychopharmacology. 2014 Apr;39(5):1222-31. [6]. Rollema H, et al. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol. 2009 Mar 1;605(1-3):114-6.				
完整储备液配制表:					
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80° C, 6 months; -20° C, 1 month (sealed storage, away from moisture and light)。-80° C 储存时, 请在 6 个月内使用, -20° C 储存时, 请在 1 个月内使用。					
可选溶剂	质量溶剂体积浓度	1 mg	5 mg	10 mg	25 mg
DMSO / H2O	1 mM	3.5189 mL	17.5945 mL	35.1890 mL	87.9724 mL
	5 mM	0.7038 mL	3.5189 mL	7.0378 mL	17.5945 mL
	10 mM	0.3519 mL	1.7594 mL	3.5189 mL	8.7972 mL
	15 mM	0.2346 mL	1.1730 mL	2.3459 mL	5.8648 mL



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

	20 mM	0.1759 mL	0.8797 mL	1.7594 mL	4.3986 mL
	25 mM	0.1408 mL	0.7038 mL	1.4076 mL	3.5189 mL
	30 mM	0.1173 mL	0.5865 mL	1.1730 mL	2.9324 mL
	40 mM	0.0880 mL	0.4399 mL	0.8797 mL	2.1993 mL
	50 mM	0.0704 mL	0.3519 mL	0.7038 mL	1.7594 mL
	60 mM	0.0586 mL	0.2932 mL	0.5865 mL	1.4662 mL
	80 mM	0.0440 mL	0.2199 mL	0.4399 mL	1.0997 mL
	100 mM	0.0352 mL	0.1759 mL	0.3519 mL	0.8797 mL

备注: 如您选择水作为储备液, 请稀释至工作液后, 再用 0.22 μm 的滤膜过滤除菌后使用。



源叶